LENZ Therapeutics, Inc. $LENZ Stock Position Raised by C WorldWide Group Holding A S

C WorldWide Group Holding A S grew its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 40.0% in the 1st quarter, Holdings Channel reports. The institutional investor owned 700,000 shares of the company’s stock after acquiring an additional 200,000 shares during the period. C WorldWide Group Holding A S’s holdings in LENZ Therapeutics were worth $6,405,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Quarry LP bought a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at approximately $27,000. Osaic Holdings Inc. lifted its stake in LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after acquiring an additional 477 shares during the last quarter. State of Wyoming bought a new stake in LENZ Therapeutics in the fourth quarter worth approximately $30,000. Finally, BNP Paribas Financial Markets grew its position in LENZ Therapeutics by 93.7% in the second quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock worth $57,000 after acquiring an additional 944 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a report on Tuesday, July 7th. Weiss Ratings upgraded shares of LENZ Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 17th. Wall Street Zen downgraded shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Citigroup cut their target price on LENZ Therapeutics from $26.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Piper Sandler cut LENZ Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $39.00 to $12.00 in a research report on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, LENZ Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.80.

LENZ Therapeutics Price Performance

LENZ Therapeutics stock opened at $4.88 on Friday. The firm has a market cap of $152.99 million, a price-to-earnings ratio of -1.36 and a beta of 0.62. LENZ Therapeutics, Inc. has a fifty-two week low of $4.68 and a fifty-two week high of $50.40. The firm has a fifty day moving average price of $6.65 and a two-hundred day moving average price of $10.73.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.22). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.76 million. LENZ Therapeutics had a negative net margin of 519.30% and a negative return on equity of 46.82%. As a group, sell-side analysts expect that LENZ Therapeutics, Inc. will post -4.63 earnings per share for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.